Aerie Pharmaceuticals reported $-33643000 in Operating Profit for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Profit Change
Aerie Pharmaceuticals AERI:US $ -33.64M 85.38M
Alimera Sciences ALIM:US $ -4.15M 1.4M
Amarin AMRN:US $ -28.31M 44.44M
Bluebird Bio BLUE:US $ -120.35M 15.32M
Cara Therapeutics CARA:US $ -27911000 5.61M
Coherus Biosciences CHRS:US $ -87.15M 47.6M
Endo International Ordinary Shares ENDP:US $ 68.99M 481.35M
Horizon Pharma HZNP:US $ 194.32M 38.77M
Insmed INSM:US $ -89833000 9.24M
JAZZ PHA JAZZ:US $ 87.55M 38.17M
Merk MRK:US $ 5569M 1994M
Mirati Therapeutics MRTX:US $ -184.22M 12.86M
Novartis NOVN:VX 2.85B 290M
Ophthotech OPHT:US $ -34.67M 1.57M
Pacira Pharmaceuticals PCRX:US $ 17.39M 13.18M
Regeneron Pharmaceuticals REGN:US $ 1258.5M 1381.2M
Revance Therapeutics RVNC:US $ -62221000 617K
Supernus Pharmaceuticals SUPN:US $ 1.97M 4.13M
Teva Pharmaceutical Industries TEVA:US $ -713M 791M
Valeant Pharmaceuticals VRX:CN $ 285M 82M
Zoetis ZTS:US $ 727M 221M